Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

Purpose This multicenter, double-blind, placebo-controlled crossover study evaluated the efficacy of a new oral contraceptive (OC) formulation containing drospirenone 3 mg and ethinyl estradiol (EE) 20 ��g in treating symptoms of premenstrual dysphoric disorder (PMDD). Method The OC formulation or placebo was administered for 24 days in a 28-day cycle (24/4), rather than the usual 21-day active treatment, 7-day inert-pill regimen. Participants...